Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Human Vaccines
|
October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
Farshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
The Lancet. Infectious Diseases
|
June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
D Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2006
A live, attenuated recombinant West Nile virus vaccine
Thomas P Monath, Jian Liu, Niranjan Kanesa-Thasan, et al.
Plos One
|
November 12, 2015
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, et al.
Vaccine: X
|
August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Thomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Plos One
|
June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
Richard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One
|
October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Integrative and Comparative Biology
|
June 16, 2011
Neuromechanics: an integrative approach for understanding motor control
Kiisa Nishikawa, Andrew A Biewener, Peter Aerts, et al.
The American Journal of Tropical Medicine and Hygiene
|
March 3, 2005
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru
Vivian E Belmusto-Worn, Jose L Sanchez, Karen McCarthy, et al.
Plos Pathogens
|
June 27, 2022
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
Thomas P Monath, Richard Nichols, Lynda Tussey, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Human Vaccines
|
October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes
Farshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
The Lancet. Infectious Diseases
|
June 14, 2017
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
D Gray Heppner, Tracy L Kemp, Brian K Martin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 18, 2006
A live, attenuated recombinant West Nile virus vaccine
Thomas P Monath, Jian Liu, Niranjan Kanesa-Thasan, et al.
Plos One
|
November 12, 2015
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, et al.
Vaccine: X
|
August 7, 2019
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Thomas P Monath, Patricia E Fast, Kayvon Modjarrad, et al.
Plos One
|
June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
Richard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One
|
October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Richard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Integrative and Comparative Biology
|
June 16, 2011
Neuromechanics: an integrative approach for understanding motor control
Kiisa Nishikawa, Andrew A Biewener, Peter Aerts, et al.
The American Journal of Tropical Medicine and Hygiene
|
March 3, 2005
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru
Vivian E Belmusto-Worn, Jose L Sanchez, Karen McCarthy, et al.
Plos Pathogens
|
June 27, 2022
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
Thomas P Monath, Richard Nichols, Lynda Tussey, et al.
Page
of 8